Loading...

Uscom

ASX:UCM
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
UCM
ASX
A$22M
Market Cap
  1. Home
  2. AU
  3. Healthcare
Company description

Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices worldwide. The last earnings update was 54 days ago. More info.


Add to Portfolio Compare Print
  • Uscom has significant price volatility in the past 3 months.
UCM Share Price and Events
7 Day Returns
3.2%
ASX:UCM
4.1%
AU Medical Equipment
-0%
AU Market
1 Year Returns
-20%
ASX:UCM
-3.3%
AU Medical Equipment
4.9%
AU Market
UCM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Uscom (UCM) 3.2% 3.2% 33.3% -20% -20% -42.9%
AU Medical Equipment 4.1% -0.5% 1.1% -3.3% 38.7% 103.7%
AU Market -0% 1% 6.3% 4.9% 18.2% 4.8%
1 Year Return vs Industry and Market
  • UCM underperformed the Medical Equipment industry which returned -3.3% over the past year.
  • UCM underperformed the Market in Australia which returned 4.9% over the past year.
Price Volatility
UCM
Industry
5yr Volatility vs Market

UCM Value

 Is Uscom undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Uscom. This is due to cash flow or dividend data being unavailable. The share price is A$0.16.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Uscom's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Uscom's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:UCM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$-0.01
ASX:UCM Share Price ** ASX (2019-04-17) in AUD A$0.16
Australia Medical Equipment Industry PE Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 33.38x
Australia Market PE Ratio Median Figure of 544 Publicly-Listed Companies 16.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Uscom.

ASX:UCM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:UCM Share Price ÷ EPS (both in AUD)

= 0.16 ÷ -0.01

-13.81x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Uscom is loss making, we can't compare its value to the AU Medical Equipment industry average.
  • Uscom is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Uscom's expected growth come at a high price?
Raw Data
ASX:UCM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -13.81x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Oceania Medical Equipment Industry PEG Ratio Median Figure of 5 Publicly-Listed Medical Equipment Companies 2.62x
Australia Market PEG Ratio Median Figure of 360 Publicly-Listed Companies 1.35x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Uscom, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Uscom's assets?
Raw Data
ASX:UCM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.03
ASX:UCM Share Price * ASX (2019-04-17) in AUD A$0.16
Australia Medical Equipment Industry PB Ratio Median Figure of 30 Publicly-Listed Medical Equipment Companies 2.72x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.67x
ASX:UCM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:UCM Share Price ÷ Book Value per Share (both in AUD)

= 0.16 ÷ 0.03

5.33x

* Primary Listing of Uscom.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Uscom is overvalued based on assets compared to the AU Medical Equipment industry average.
X
Value checks
We assess Uscom's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Uscom has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

UCM Future Performance

 How is Uscom expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Uscom has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.2%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Uscom expected to grow at an attractive rate?
  • Unable to compare Uscom's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Uscom's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Uscom's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:UCM Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 13.2%
Australia Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.4%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.6%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:UCM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:UCM Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 3 -1 -2
2018-09-30 3 -1 -2
2018-06-30 3 -2 -2
2018-03-31 3 -1 -2
2017-12-31 3 -1 -2
2017-09-30 3 -1 -2
2017-06-30 3 -1 -2
2017-03-31 3 -1 -2
2016-12-31 3 -1 -2
2016-09-30 3 -1 -2
2016-06-30 3 -1 -2
2016-03-31 3 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Uscom is high growth as no earnings estimate data is available.
  • Unable to determine if Uscom is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:UCM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Uscom Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:UCM Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 -0.01
2018-09-30 -0.01
2018-06-30 -0.02
2018-03-31 -0.02
2017-12-31 -0.02
2017-09-30 -0.02
2017-06-30 -0.02
2017-03-31 -0.02
2016-12-31 -0.02
2016-09-30 -0.02
2016-06-30 -0.02
2016-03-31 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Uscom will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Uscom's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Uscom's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. Uscom's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Uscom's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Uscom has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

UCM Past Performance

  How has Uscom performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Uscom's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Uscom does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Uscom's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Uscom's 1-year growth to the AU Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Uscom's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Uscom Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:UCM Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 2.92 -1.63 4.04
2018-09-30 2.89 -1.80 4.12
2018-06-30 2.86 -1.96 4.21
2018-03-31 2.94 -2.00 4.25
2017-12-31 3.02 -2.04 4.29
2017-09-30 3.26 -1.92 4.43
2017-06-30 3.50 -1.80 4.58
2017-03-31 3.43 -1.86 4.57
2016-12-31 3.36 -1.92 4.56
2016-09-30 3.15 -1.92 4.35
2016-06-30 2.94 -1.92 4.13
2016-03-31 2.67 -1.79 3.85
2015-12-31 2.41 -1.66 3.56
2015-09-30 2.22 -1.44 3.21
2015-06-30 2.04 -1.22 2.85
2015-03-31 2.07 -1.24 2.78
2014-12-31 2.10 -1.26 2.70
2014-09-30 1.74 -1.39 2.59
2014-06-30 1.38 -1.52 2.48
2014-03-31 1.02 -1.44 2.33
2013-12-31 0.66 -1.35 2.17
2013-09-30 0.65 -1.36 2.20
2013-06-30 0.64 -1.37 2.23
2013-03-31 0.68 -1.37 2.26
2012-12-31 0.72 -1.36 2.29
2012-09-30 0.79 -1.59 2.55
2012-06-30 0.86 -1.82 2.80

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Uscom has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Uscom has efficiently used its assets last year compared to the AU Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Uscom improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Uscom's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Uscom has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

UCM Health

 How is Uscom's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Uscom's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Uscom is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Uscom's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Uscom's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Uscom has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Uscom Company Filings, last reported 3 months ago.

ASX:UCM Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 4.13 0.00 2.18
2018-09-30 4.13 0.00 2.18
2018-06-30 4.84 0.00 2.49
2018-03-31 4.84 0.00 2.49
2017-12-31 5.70 0.00 3.49
2017-09-30 5.70 0.00 3.49
2017-06-30 3.78 0.00 1.71
2017-03-31 3.78 0.00 1.71
2016-12-31 4.62 0.00 1.88
2016-09-30 4.62 0.00 1.88
2016-06-30 4.94 0.00 2.84
2016-03-31 4.94 0.00 2.84
2015-12-31 3.64 0.00 1.07
2015-09-30 3.64 0.00 1.07
2015-06-30 2.29 0.00 0.53
2015-03-31 2.29 0.00 0.53
2014-12-31 2.98 0.00 1.00
2014-09-30 2.98 0.00 1.00
2014-06-30 3.32 0.00 1.58
2014-03-31 3.32 0.00 1.58
2013-12-31 2.82 0.00 0.76
2013-09-30 2.82 0.00 0.76
2013-06-30 2.35 0.00 0.54
2013-03-31 2.35 0.00 0.54
2012-12-31 1.91 0.00 0.90
2012-09-30 1.91 0.00 0.90
2012-06-30 1.47 0.00 0.54
  • Uscom has no debt.
  • Uscom has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Uscom has sufficient cash runway for 1.7 years based on current free cash flow.
  • Uscom has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 6% each year.
X
Financial health checks
We assess Uscom's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Uscom has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

UCM Dividends

 What is Uscom's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Uscom dividends.
If you bought A$2,000 of Uscom shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Uscom's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Uscom's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:UCM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Oceania Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1.7%
Australia Market Average Dividend Yield Market Cap Weighted Average of 417 Stocks 4.3%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.6%
Australia Bottom 25% Dividend Yield 25th Percentile 2.5%
Australia Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Uscom has not reported any payouts.
  • Unable to verify if Uscom's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Uscom's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Uscom has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Uscom's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Uscom afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Uscom has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

UCM Management

 What is the CEO of Uscom's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rob Phillips
COMPENSATION A$851,447
AGE 65
CEO Bio

Dr. Robert A. Phillips, also known as Rob, Ph.D.(Med), MPhil (Med), FASE, DMU, AMS, FIR, is the Founder of Uscom Limited and serves as its Chief Scientist. Dr. Phillips has been the Chief Executive Officer of USCOM Ltd. since December 2011. He served as the Chief Science Officer, Director of Clinical Science and Director of Medical Science of USCOM Ltd. He is the inventor of the USCOM Monitor. He was responsible for the science, applications and clinical credentials of USCOM Ltd. Dr. Phillips' work has been peer reviewed for presentation to the world's most important cardiovascular events. He is a recognised pioneer in his field, being the first person in Australia to use digital ultrasound as a standard diagnostic system. Dr. Phillips research in Echocardiography has earned him both national and international recognition. Dr. Phillips has presented at some of the world's most prestigious cardiology conferences, including the World Congress of Echocardiography and the World Congress of Cardiology. He serves as the Chairman of Medical and Technology Advisory Board at USCOM Ltd., is responsible for the supervision of USCOM Ltd.'s research activities, clinical trials, scientific collaborations and management of USCOM Ltd.'s patent portfolio. He serves as the Executive Chairman of USCOM Ltd. He holds the following positions or is a Member of the following organisations: Dr. Phillips is a Fellow of the Institute of Radiology; Diploma of Medical Ultrasound (Cardiology); Head of the Cardiac Faculty of the Australian Institute of Ultrasound, Chair of the Cardiac Education & Standards Sub-Committee of the Australian Society of Ultrasound in Medicine, Co-coordinator and Faculty Member of the ASUM DMU Cardiology course for Australia's most prestigious ultrasound qualification and Adviser to the NSW Government on ultrasound practice funding. In addition to the above appointments, Dr. Phillips has presented the following papers in recent years: Faculty presentation in relation to the USCOM Monitor to the World Congress of Echocardiography in Seoul, Korea in May 2001, Faculty presentation to the International Society of Cardiovascular Ultrasound, Anaheim California in November 2001 and World Congress of Echocardiography, Buenos Aires, Argentina in October 2003. He is the author of over 25 patents and patent applications relating to assessment of cardiovascular performance and measurement. Dr. Phillips holds a Master of Philosophy in Medicine from the University of Queensland.

CEO Compensation
  • Rob's compensation has increased whilst company is loss making.
  • Rob's remuneration is lower than average for companies of similar size in Australia.
Management Team

Rob Phillips

TITLE
Founder
COMPENSATION
A$851K
AGE
65

Nick Schicht

TITLE
General Manager
COMPENSATION
A$226K
AGE
52

Brett Crowley

TITLE
Company Secretary & Executive Director
AGE
61
TENURE
2.9 yrs
Board of Directors

Brett Crowley

TITLE
Company Secretary & Executive Director
AGE
61
TENURE
0.7 yrs

Malcolm West

TITLE
Member of Medical & Technology Advisory Board

Rob Phillips

TITLE
Founder
COMPENSATION
A$851K
AGE
65

Colin Sullivan

TITLE
Member of Medical & Technology Advisory Board

Stephane Carlier

TITLE
Member of Medical & Technology Advisory Board

Chu-Pak Lau

TITLE
Member of Medical & Technology Advisory Board

Didier Payen

TITLE
Member of Medical & Technology Advisory Board

Peter Lichtenthal

TITLE
Member of Medical & Technology Advisory Board

Christian Bernecker

TITLE
Non-Executive Director
COMPENSATION
A$38K
TENURE
7.4 yrs

Nigel Sharrock

TITLE
Member of Medical & Technology Advisory Board
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Uscom insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
21. Mar 19 Buy Xianhui Meng Individual 12. Mar 19 19. Mar 19 1,450,007 A$0.15 A$215,032
14. Jun 18 Buy Robert Phillips Individual 06. Jun 18 06. Jun 18 7,000 A$0.17 A$1,190
X
Management checks
We assess Uscom's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Uscom has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

UCM News

Simply Wall St News

Uscom Limited's (ASX:UCM) Earnings Dropped -8.9%, Did Its Industry Show Weakness Too?

Assessing Uscom Limited's (ASX:UCM) past track record of performance is a valuable exercise for investors. … Today I will assess UCM's recent performance announced on 30 June 2018 and evaluate these figures to its longer term trend and industry movements. … UCM is loss-making, with the most recent trailing twelve-month earnings of -AU$2.0m (from 30 June 2018), which compared to last year has become.

Simply Wall St -

Does The Uscom Limited (ASX:UCM) Share Price Fall With The Market?

If you're interested in Uscom Limited (ASX:UCM), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility).

Simply Wall St -

What Type Of Shareholder Owns Uscom Limited's (ASX:UCM)?

A look at the shareholders of Uscom Limited (ASX:UCM) can tell us which group is most powerful. … Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Uscom is not a large company by global standards.

Simply Wall St -

Where Uscom Limited's (ASX:UCM) Earnings Growth Stands Against Its Industry

When Uscom Limited (ASX:UCM) released its most recent earnings update (30 June 2018), I compared it against two factor: its historical earnings track record, and the performance of its industry peers on average. … UCM is loss-making, with the most recent trailing twelve-month earnings of -AU$2m (from 30 June 2018), which compared to last year has become. … Furthermore, the company's loss seem to be growing over time, with the five-year earnings average of -AU$2m

Simply Wall St -

Can Uscom Limited (ASX:UCM) Improve Your Portfolio Returns?

If you are looking to invest in Uscom Limited’s (ASX:UCM), or currently own the stock, then you need to understand its beta in order to understand how it can affect the risk of your portfolio. … Different characteristics of a stock expose it to various levels of market risk. … The most widely used metric to quantify a stock's market risk is beta, and the market as a whole represents a beta of one.

Simply Wall St -

Uscom Limited (ASX:UCM): Should The Recent Earnings Drop Worry You?

Today I will assess UCM's recent performance announced on 31 December 2017 and compare these figures to its long-term trend and industry movements. … Was UCM's recent earnings decline worse than the long-term trend and the industry. … UCM is loss-making, with the most recent trailing twelve-month earnings of -AU$2.04m (from 31 December 2017), which compared to last year has become.

Simply Wall St -

Does Uscom Limited (ASX:UCM) Go Up With The Market?

A widely-used metric to measure a stock's market risk is beta, and the broad market index represents a beta value of one. … A stock with a beta greater than one is considered more sensitive to market-wide shocks compared to a stock that trades below the value of one. … Based on this beta value, UCM appears to be a stock that an investor with a high-beta portfolio would look for to reduce risk exposure to the market.

Simply Wall St -

Does Uscom Limited's (ASX:UCM) CEO Pay Compare Well With Peers?

Earnings is a powerful indication of UCM's ability to invest shareholders' funds and generate returns. … Therefore I will use earnings as a proxy of Phillips's performance in the past year. … Usually I would look at market cap and earnings as a proxy for performance, however, UCM's negative earnings reduces the effectiveness of this method.

Simply Wall St -

Should You Sell Uscom Limited (ASX:UCM) For This Reason?

The measure of how fast Uscom goes through its cash reserves over time is called the cash burn rate. … Not surprisingly, if Uscom continues to ramp up expenditure at this rate for the upcoming year, it’ll likely need to come to market within the next few months, given the its current level of cash reserves. … The cash burn analysis result indicates a cash constraint for the company, due to its high opex growth and its level of cash reserves.

Simply Wall St -

Who Really Owns Uscom Limited (ASX:UCM)?

Check out our latest analysis for Uscom ASX:UCM Ownership_summary Mar 16th 18 Institutional Ownership Institutional investors are one of the largest group of market participants and their buy-sell decisions on a company's stock can significantly impact prices, more so, when there are relatively small amounts of shares available on the market to trade. … Insider Ownership Another important group of shareholders are company insiders. … Thus, potential investors should look into these business relations and check how it can impact long-term shareholder returns.Next Steps: Institutional ownership level and composition in UCM is not high nor active enough to significantly impact its investment thesis.

Simply Wall St -

UCM Company Info

Description

Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices worldwide. The company offers USCOM 1A, a non-invasive hemodynamic monitor that measures cardiovascular function using Doppler ultrasound; BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, as well as in the arm; and SpiroSonic, a pulmonary function testing device based on multi-path ultrasound technology. It serves hospitals and other medical care locations through a network of distribution partners. The company was incorporated in 1999 and is headquartered in Sydney, Australia.

Details
Name: Uscom Limited
UCM
Exchange: ASX
Founded: 1999
A$22,022,538
137,640,866
Website: http://www.uscom.com.au
Address: Uscom Limited
66 Clarence Street,
Suite 2,
Sydney,
New South Wales, 2000,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX UCM Ordinary Shares Australian Securities Exchange AU AUD 10. Dec 2003
CHIA UCM Ordinary Shares Chi-X Australia AU AUD 10. Dec 2003
Number of employees
Current staff
Staff numbers
0
Uscom employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 10:32
End of day share price update: 2019/04/17 00:00
Last earnings filing: 2019/02/27
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.